Bayer will allocate up to $1 million in grants to support clinical research in pulmonary hypertension, with a focus in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Bayer, the global biopharmaceutical company has announced its “Pulmonary Hypertension Accelerated Awards,” a new program it launched to support investigators with a focus on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

The grant applications are open to physician practitioners and nonphysicians in the United States starting May 28 through June 30, 2019. Applicants will be expected to submit letters of intent with a short proposal that will be reviewed by an independent Grants Review Committee of 6 to 8 leading medical experts. After the initial evaluation, applicants will be invited to submit a full proposal by August 31, 2019.   Follow the link to the source below for more information—Bayer’s contact: e-mail PHAB.awards@bayer.com

Source: PR Newswire

Pin It on Pinterest